NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA
NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT02564900 2024-01-22Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsDaiichi SankyoPhase 1 Completed292 enrolled 35 charts 1 FDA